Clinical Trial

Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)

Name: Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) — clinical trial record (NCT06387056)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: SEGNO

Recruiting Phase 2

View on ClinicalTrials.gov →

Record status

This record was last updated April 26, 2024 (before its estimated April 1, 2026 completion). Its status may not reflect the trial's current state.

Summary

To evaluated the safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer.

Trial Details

NCT Number	NCT06387056
Lead Sponsor	The First Affiliated Hospital of Xiamen University
Conditions	Locally Advanced Prostate Cancer, Oligometastatic Prostate Cancer
Enrollment	40 participants
Start Date	2024-04-01
Primary Completion	2026-04-01 (estimated)
Study Completion	2029-04-01 (estimated)
Updated on ClinicalTrials.gov	2024-04-26